Atara Biotherapeutics, Inc. (ATRA) Reaches $41.40 After 6.00% Down Move; Polaris Industries (PII) Shorts Decreased By 11.43%

February 23, 2018 - By reb123z

Polaris Industries Inc (NYSE:PII) had a decrease of 11.43% in short interest. PII’s SI was 7.65M shares in February as released by FINRA. Its down 11.43% from 8.64 million shares previously. With 985,500 avg volume, 8 days are for Polaris Industries Inc (NYSE:PII)’s short sellers to cover PII’s short positions. The SI to Polaris Industries Inc’s float is 13.18%. The stock decreased 0.72% or $0.84 during the last trading session, reaching $115.33. About 94,982 shares traded. Polaris Industries Inc. (NYSE:PII) has risen 5.51% since February 23, 2017 and is uptrending. It has underperformed by 11.19% the S&P500.

The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is a huge mover today! The stock decreased 3.50% or $1.5005 during the last trading session, reaching $41.3995. About 190,173 shares traded. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has declined 7.28% since February 23, 2017 and is downtrending. It has underperformed by 23.98% the S&P500.The move comes after 7 months negative chart setup for the $1.56B company. It was reported on Feb, 23 by Barchart.com. We have $38.92 PT which if reached, will make NASDAQ:ATRA worth $93.36M less.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. The company has market cap of $1.56 billion. The Company’s clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. It currently has negative earnings. The firm is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease.

Investors sentiment increased to 1.54 in 2017 Q3. Its up 0.26, from 1.28 in 2017Q2. It improved, as 8 investors sold Atara Biotherapeutics, Inc. shares while 16 reduced holdings. 9 funds opened positions while 28 raised stakes. 26.16 million shares or 3.51% more from 25.27 million shares in 2017Q2 were reported. Camber Capital Mgmt Ltd Llc holds 0.56% or 535,500 shares in its portfolio. Bnp Paribas Arbitrage holds 2,442 shares. Goldman Sachs Group Incorporated holds 19,956 shares or 0% of its portfolio. Massachusetts-based Geode Cap Management Lc has invested 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Retail Bank Of Montreal Can reported 4,591 shares. Tiaa Cref Investment Mngmt Ltd Liability invested in 0% or 63,812 shares. Alliancebernstein Lp reported 27,740 shares stake. Old West Invest Management Limited Liability Corp owns 20,895 shares. Moreover, Citigroup has 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 80 shares. Perceptive Limited Liability Company invested in 35,106 shares or 0.02% of the stock. Bancshares Of America Corp De holds 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 200,364 shares. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Mngmt Corporation holds 0.01% or 39,330 shares. Dekabank Deutsche Girozentrale has 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Proshare Advsrs Ltd Liability Corporation accumulated 18,963 shares. Northern Tru Corp holds 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 286,973 shares.

Analysts await Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to report earnings on March, 8. They expect $-1.14 earnings per share, down 80.95% or $0.51 from last year’s $-0.63 per share. After $-1.02 actual earnings per share reported by Atara Biotherapeutics, Inc. for the previous quarter, Wall Street now forecasts 11.76% negative EPS growth.

Among 7 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. Atara Biotherapeutics had 21 analyst reports since September 9, 2015 according to SRatingsIntel. Canaccord Genuity maintained Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Tuesday, January 30 with “Buy” rating. Jefferies maintained it with “Buy” rating and $30.0 target in Thursday, August 31 report. The firm earned “Market Outperform” rating on Tuesday, December 15 by JMP Securities. The firm has “Sell” rating given on Monday, August 22 by Citigroup. The rating was reinitiated by Jefferies on Thursday, June 22 with “Buy”. The company was upgraded on Wednesday, January 3 by Citigroup. JMP Securities initiated the stock with “Mkt Perform” rating in Friday, September 25 report. As per Friday, October 9, the company rating was initiated by William Blair. Citigroup maintained Atara Biotherapeutics, Inc. (NASDAQ:ATRA) rating on Friday, August 19. Citigroup has “Sell” rating and $8 target. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) earned “Neutral” rating by Goldman Sachs on Wednesday, November 18.

Since September 6, 2017, it had 0 insider purchases, and 17 selling transactions for $7.40 million activity. Ciechanover Isaac E. sold 19,300 shares worth $680,534. The insider Haqq Christopher sold 6,000 shares worth $91,800. $464,210 worth of stock was sold by Turner Heather D on Friday, February 9. The insider Gallagher Carol Giltner sold 1,183 shares worth $55,010. $611,925 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) was sold by MCGRATH JOHN.

Investors sentiment decreased to 0.72 in 2017 Q3. Its down 0.49, from 1.21 in 2017Q2. It worsened, as 35 investors sold Polaris Industries Inc. shares while 152 reduced holdings. 46 funds opened positions while 89 raised stakes. 56.03 million shares or 4.63% less from 58.75 million shares in 2017Q2 were reported. Arrowstreet L P stated it has 0% in Polaris Industries Inc. (NYSE:PII). Fjarde Ap accumulated 0.03% or 17,183 shares. Midas Management Corp accumulated 1.26% or 22,800 shares. Capital Services Of America stated it has 80,750 shares or 1.42% of all its holdings. Nationwide Fund Advisors has 98,109 shares for 0.04% of their portfolio. Legal And General Pcl accumulated 298,548 shares. Tiemann Advisors Ltd Liability Co holds 1.4% or 15,825 shares in its portfolio. Geode Limited Liability Corporation reported 462,369 shares or 0.02% of all its holdings. State Of Tennessee Treasury Department, a Tennessee-based fund reported 125,700 shares. D E Shaw & Company Incorporated invested 0% in Polaris Industries Inc. (NYSE:PII). Raymond James And accumulated 414,222 shares or 0.09% of the stock. Stephens Ar stated it has 10,076 shares or 0.04% of all its holdings. Eqis holds 2,924 shares or 0.02% of its portfolio. Thrivent For Lutherans accumulated 121,292 shares or 0.04% of the stock. Voya Invest Llc has invested 0.01% in Polaris Industries Inc. (NYSE:PII).

Polaris Industries Inc. designs, engineers, makes, and markets power sports vehicles worldwide. The company has market cap of $7.27 billion. It operates through four divisions: Off-Road Vehicles /Snowmobiles, Motorcycles, Global Adjacent Markets, and Other. It has a 42.87 P/E ratio. The firm provides ORVs, including all-terrain vehicles and side-by-side vehicles for recreational, military, and utility use; snowmobiles and technical riding gears; three-wheel motorcycles; and low emission, light duty hauling, passenger, commercial, and industrial vehicles.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>